126 related articles for article (PubMed ID: 38710299)
1. EGC enhances tumor antigen presentation and CD8
Zhang X; Cui X; Li P; Zhao Y; Ren Y; Zhang H; Zhang S; Li C; Wang X; Shi L; Sun T; Hao J; Yao Z; Chen J; Gao X; Yang J
Cancer Lett; 2024 Jun; 592():216934. PubMed ID: 38710299
[TBL] [Abstract][Full Text] [Related]
2. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
3. Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8
Wang Y; Wang X; Cui X; Zhuo Y; Li H; Ha C; Xin L; Ren Y; Zhang W; Sun X; Ge L; Liu X; He J; Zhang T; Zhang K; Yao Z; Yang X; Yang J
Sci Adv; 2020 May; 6(22):. PubMed ID: 32917674
[TBL] [Abstract][Full Text] [Related]
4. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
5. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
[TBL] [Abstract][Full Text] [Related]
6. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.
Matheoud D; Baey C; Vimeux L; Tempez A; Valente M; Louche P; Le Bon A; Hosmalin A; Feuillet V
PLoS One; 2011 Apr; 6(4):e19104. PubMed ID: 21552572
[TBL] [Abstract][Full Text] [Related]
8. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
9. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
10. MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells.
Wang X; Waschke BC; Woolaver RA; Chen SMY; Chen Z; Wang JH
Cell Mol Immunol; 2021 Mar; 18(3):723-734. PubMed ID: 32427883
[TBL] [Abstract][Full Text] [Related]
11. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
12. Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8
Clancy-Thompson E; Devlin CA; Tyler PM; Servos MM; Ali LR; Ventre KS; Bhuiyan MA; Bruck PT; Birnbaum ME; Dougan SK
Cancer Immunol Res; 2018 Dec; 6(12):1524-1536. PubMed ID: 30352798
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
14. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
15. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
[TBL] [Abstract][Full Text] [Related]
17. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
18. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
19. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
20. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation.
Deng G; Zhou L; Wang B; Sun X; Zhang Q; Chen H; Wan N; Ye H; Wu X; Sun D; Sun Y; Cheng H
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36307151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
